Along with serving as a novel treatment modality for patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), the gemcitabine intravesical system (formerly TAR-200; Inlexzo) could serve as a technique to help patients avoid…
FDA Approval of TAR-200 Represents Potential Bladder-Sparing Option in BCG-Unresponsive NMIBC
